how has talapro-2 changed the standard of care for first-line mcrpc with hrr mutations?
Published 1 year ago • 48 plays • Length 8:00Download video MP4
Download video MP3
Similar videos
-
0:52
talapro-2 study design for 1l in mcrpc patients - now fda approved | #oncology #cancer #2023
-
1:19
talapro-2: exploratory analyses of hrr gene subgroups in mcrpc
-
5:01
talazoparib plus enzalutamide shows improvement in pfs over soc in first-line hrr mcrpc
-
0:39
talapro-2: rpfs and os of talazoparib and enzalutamide in mcrpc
-
8:56
talapro-2: phase 3 results of talazoparib plus enzalutamide for mcrpc
-
6:54
talapro-2: toxicities and treatment duration
-
11:19
drs. fizazi, wallis on updated data from talapro-2
-
29:13
evolving treatment landscape for mhspc: latest clinical data and implications for practice
-
9:20
the importance of molecular testing for hrr gene mutations in patients with mcrpc
-
4:08
propel: final os of first-line abiraterone plus olaparib for mcrpc
-
18:58
talapro-2 study of talazoparib/enzalutamide in prostate cancer: stephen freedland and neeraj agarwal
-
6:41
esmo expert report on combination therapy in advanced prostate cancer @ asco gu 2022
-
9:25
hrr mutation testing in crpc: improving time to testing after diagnosis
-
1:37
dr. agarwal on the talapro-2 trial in mcrpc
-
3:47
elucidating hrrm status in patients with mcrpc in the propel trial
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
12:24
gu asco symposium 2022 summary
-
8:21
ep. 10: how has the mcrpc treatment landscape changed?
-
5:36
propel trial